- Home
- MDXG vs PHVS Comparison
MDXG vs PHVS Comparison
Compare MDXG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXG
- PHVS
- Stock Information
- Founded
- MDXG 2006
- PHVS 2015
- Country
- MDXG United States
- PHVS Switzerland
- Employees
- MDXG N/A
- PHVS N/A
- Industry
- MDXG Biotechnology: Pharmaceutical Preparations
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- MDXG Health Care
- PHVS Health Care
- Exchange
- MDXG Nasdaq
- PHVS Nasdaq
- Market Cap
- MDXG 877.4M
- PHVS 980.9M
- IPO Year
- MDXG N/A
- PHVS 2021
- Fundamental
- Price
- MDXG $6.33
- PHVS $22.99
- Analyst Decision
- MDXG Strong Buy
- PHVS Buy
- Analyst Count
- MDXG 2
- PHVS 6
- Target Price
- MDXG $11.50
- PHVS $37.17
- AVG Volume (30 Days)
- MDXG 842.0K
- PHVS 59.1K
- Earning Date
- MDXG 07-30-2025
- PHVS 08-13-2025
- Dividend Yield
- MDXG N/A
- PHVS N/A
- EPS Growth
- MDXG N/A
- PHVS N/A
- EPS
- MDXG 0.27
- PHVS N/A
- Revenue
- MDXG $352,375,000.00
- PHVS N/A
- Revenue This Year
- MDXG $9.55
- PHVS N/A
- Revenue Next Year
- MDXG $11.43
- PHVS N/A
- P/E Ratio
- MDXG $23.26
- PHVS N/A
- Revenue Growth
- MDXG 5.34
- PHVS N/A
- 52 Week Low
- MDXG $5.47
- PHVS $11.51
- 52 Week High
- MDXG $10.14
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- MDXG 47.21
- PHVS 67.31
- Support Level
- MDXG $6.57
- PHVS $17.63
- Resistance Level
- MDXG $6.85
- PHVS $26.33
- Average True Range (ATR)
- MDXG 0.29
- PHVS 1.70
- MACD
- MDXG 0.07
- PHVS 0.65
- Stochastic Oscillator
- MDXG 39.50
- PHVS 65.24
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.